Charles W Yates Selected Research

Non-Steroidal Anti-Inflammatory Agents (NSAIDs)

1/2018

Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles W Yates Research Topics

Disease

6	Neoplasms (Cancer) 01/2021 - 09/2011
5	Neurilemmoma (Schwannoma) 01/2021 - 01/2015
3	Meningioma (Meningiomas) 01/2021 - 09/2011
1	Sensorineural Hearing Loss 01/2018
1	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2018
1	Carcinogenesis 01/2018
1	Neurofibromatoses (Neurofibromatosis) 01/2018
1	Infections 12/2017
1	Acoustic Neuroma (Acoustic Neurinoma) 09/2011
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 06/2010
1	Hematoma 06/2010

Drug/Important Bio-Agent (IBA)

4	Pharmaceutical PreparationsIBA 01/2021 - 09/2011
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2019
2	Neurofibromin 2 (Merlin)IBA 01/2019 - 01/2018
1	brigatinibIBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019
1	CaspasesIBA 01/2019
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2018
1	Celecoxib (Celebrex)FDA Link 01/2018
1	Drug CombinationsIBA 01/2018
1	PanobinostatIBA 01/2018
1	omipalisibIBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2017
1	Histone Deacetylase InhibitorsIBA 09/2011

Therapy/Procedure

5	Therapeutics 01/2021 - 06/2010
1	Aftercare (After-Treatment) 01/2018
1	Drug Therapy (Chemotherapy) 01/2018
1	Craniotomy 06/2010